HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Appropriations

This article was originally published in The Tan Sheet

Executive Summary

Agriculture appropriations bill providing funding for FDA and the WIC nutrition program (HR 4461) will likely be paired with the transportation spending bill (HR 4475) to expedite passage, but a final decision is still up in the air, according to the House Appropriations Committee. Separately, the House passed a continuing resolution Sept. 26 to keep the government operating until Oct. 6 pending completion of 11 FY 2001 spending measures, including the Labor/HHS bill, which contains funding for the National Center for Complementary & Alternative Medicine and the Office of Dietary Supplements. The Senate version allocates $20.5 bil. to NIH, while the House set funding at $18.8 bil. (1"The Tan Sheet" May 15, In Brief)

You may also be interested in...



NIH funding

Senate Appropriations Committee approves FY 2001 Labor/HHS funding in unanimous vote May 11. Agency is provided with $20.5 bil., $2.7 bil. over FY 2000 and $1.7 bil. over President Clinton's request. The House version sets $18.8 bil. budget for NIH in FY 2001, a $1 bil. increase over FY 2000; House approps were in line with the president's request

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS133475

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel